Eisai Co., Ltd. (TYO:4523)
Japan · Delayed Price · Currency is JPY 4,311.00
+41.00 (0.96%)
At close: Jan 30, 2026
Eisai Employees
Eisai had 10,917 employees as of March 31, 2025. The number of employees decreased by 150 or -1.36% compared to the previous year.
Employees
10,917
Change (1Y)
-150
Growth (1Y)
-1.36%
Revenue / Employee
73.68M JPY
Profits / Employee
4.52M JPY
Market Cap
1.22T
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2025 | 10,917 | -150 | -1.36% |
| Mar 31, 2024 | 11,067 | -9 | -0.08% |
| Mar 31, 2023 | 11,076 | -246 | -2.17% |
| Mar 31, 2022 | 11,322 | 85 | 0.76% |
| Mar 31, 2021 | 11,237 | 239 | 2.17% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Takeda Pharmaceutical Company | 47,455 |
| Toho Holdings | 7,609 |
| Shionogi & | 4,955 |
| Towa Pharmaceutical | 4,788 |
| Tsumura & Co. | 4,272 |
| Sumitomo Pharma | 3,832 |
| Sawai Group Holdings | 3,310 |
| Hisamitsu Pharmaceutical Co. | 2,799 |
Eisai News
- 6 days ago - FDA Accepts To Priority Review Eisai And Biogen's LEQEMBI SBLA For Early Alzheimer's Disease - Nasdaq
- 6 days ago - FDA Grants Priority Review To Eisai And Biogen's SBLA For LEQEMBI Subcutaneous Autoinjector - Nasdaq
- 6 days ago - FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review - Benzinga
- 6 days ago - FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review - Benzinga
- 18 days ago - LARGE CAP INTERNATIONAL PORTFOLIO Buys Shares of Eisai Co Ltd (4523) - GuruFocus
- 20 days ago - Nuvation Bio (NUVB) Expands Global Reach with Eisai Collaboration - GuruFocus
- 6 weeks ago - China’s new drug insurance: lifeline for patients or squeeze on big pharmaceutical firms? - South China Morning Post
- 7 weeks ago - Eisai Co., Ltd. (ESAIY) Discusses Value Creation Initiatives, ESG, and Dementia Area Contributions Transcript - Seeking Alpha